Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.

Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better ...

A troubling rise in severe diverticulitis cases among Americans under 50 highlights a significant public health concern. Recent research reveals increased hospitalization rates and complications for ...

In ENCIRCLE, TMVR was performed in very ill patients with symptomatic mitral valve disease unsuitable for surgery or commercially available transcatheter edge-to-edge repair (TEER). Given the huge ...

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...

The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.

People who underwent a minimally invasive procedure to have their heart's aortic valve replaced had similar health outcomes ...

Abbott reported new study findings supporting the use of its Tendyne transcatheter mitral valve replacement (TMVR) system.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...